The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Contacts:
Study Website: http://www.plcostars.com
Number of Enrolled Cancer Patients/Survivors: | Approx. 22,300 (diagnosed during trial) |
---|---|
Years of Diagnoses of Enrolled Cancer Patients/Survivors: | 1993-2009 |
Approximate Years of Follow-up: | 13 (Although actual follow-up is much longer, only data up to 13 years are currently available for research.) |
Cancer Sites Represented: | All sites (colon and lung are not available for research until publication of the final outcome manuscripts. We hope these data can be released in 2012.) |
Biological Specimens Collected: |
Blood/Blood Fraction (for intervention arm patients only) Buccal Cells (for control arm patients only) Germline DNA (Can be extracted) Formalin Fixed Tumor Tissue (for select cancers including colorectal, lung, prostate, ovarian and breast) |
Treatment Outcome Measures: |
Physician/Medical Record Reported (Prostate Cancer Progression Study)
|
Co-morbidities at Study Entry: |
Diabetes Heart Disease Pulmonary Disease Other (e.g., arthritis) |
Lifestyle Factors: |
Smoking Alcohol Use Diet Physical Activity (limited) Body Mass Index Other (e.g., medication use/HRT) |
Treatment Data: |
Surgery Radiation Chemotherapy Hormonal Therapy Other |
Treatment Data Assessed By: | Chart Abstraction |
Is the study open to collaboration? | Yes |